Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Receivables (2021 - 2025)

Historic Receivables for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Q3 2025 value amounting to $107.1 million.

  • Mirum Pharmaceuticals' Receivables rose 5632.86% to $107.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.1 million, marking a year-over-year increase of 5632.86%. This contributed to the annual value of $78.3 million for FY2024, which is 1518.07% up from last year.
  • Per Mirum Pharmaceuticals' latest filing, its Receivables stood at $107.1 million for Q3 2025, which was up 5632.86% from $106.8 million recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Receivables registered a high of $107.1 million during Q3 2025, and its lowest value of $400000.0 during Q3 2021.
  • Over the past 5 years, Mirum Pharmaceuticals' median Receivables value was $47.8 million (recorded in 2023), while the average stood at $47.9 million.
  • In the last 5 years, Mirum Pharmaceuticals' Receivables surged by 398425.0% in 2022 and then surged by 1518.07% in 2024.
  • Quarter analysis of 5 years shows Mirum Pharmaceuticals' Receivables stood at $3.3 million in 2021, then surged by 634.44% to $24.0 million in 2022, then soared by 183.27% to $68.0 million in 2023, then grew by 15.18% to $78.3 million in 2024, then surged by 36.85% to $107.1 million in 2025.
  • Its Receivables stands at $107.1 million for Q3 2025, versus $106.8 million for Q2 2025 and $95.9 million for Q1 2025.